La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Carl Zeiss Meditec Croissance future
Future contrôle des critères 2/6
Carl Zeiss Meditec devrait augmenter ses bénéfices et son chiffre d'affaires de 18.4% et de 8.4% par an respectivement. Le BPA devrait croître de de 18.5% par an. Le rendement des capitaux propres devrait être 12.8% dans 3 ans.
Informations clés
18.4%
Taux de croissance des bénéfices
18.5%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 17.0% |
| Taux de croissance des recettes | 8.4% |
| Rendement futur des capitaux propres | 12.8% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 19 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
At €62.50, Is It Time To Put Carl Zeiss Meditec AG (ETR:AFX) On Your Watch List?
Aug 09
Carl Zeiss Meditec AG's (ETR:AFX) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
Jul 11Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Stalled
Jun 10Carl Zeiss Meditec AG's (ETR:AFX) Popularity With Investors Is Under Threat From Overpricing
May 26Carl Zeiss Meditec AG Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 11Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
May 09Is There Now An Opportunity In Carl Zeiss Meditec AG (ETR:AFX)?
Mar 24Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Mar 11Slowing Rates Of Return At Carl Zeiss Meditec (ETR:AFX) Leave Little Room For Excitement
Feb 12Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jan 29What Does Carl Zeiss Meditec AG's (ETR:AFX) Share Price Indicate?
Dec 08Carl Zeiss Meditec (ETR:AFX) Is Experiencing Growth In Returns On Capital
Nov 08Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 37% Above Its Share Price
Oct 24Is Carl Zeiss Meditec (ETR:AFX) A Risky Investment?
Sep 24Should You Investigate Carl Zeiss Meditec AG (ETR:AFX) At €85.72?
Sep 08Calculating The Fair Value Of Carl Zeiss Meditec AG (ETR:AFX)
Jul 24We Like These Underlying Return On Capital Trends At Carl Zeiss Meditec (ETR:AFX)
Jun 19Should You Think About Buying Carl Zeiss Meditec AG (ETR:AFX) Now?
Jun 06Is Now The Time To Put Carl Zeiss Meditec (ETR:AFX) On Your Watchlist?
May 22Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 24% Below Its Share Price
Apr 19Carl Zeiss Meditec (ETR:AFX) Has A Pretty Healthy Balance Sheet
Feb 26Carl Zeiss Meditec's (ETR:AFX) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 10Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Jan 28Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Jan 12Carl Zeiss Meditec (ETR:AFX) Will Pay A Larger Dividend Than Last Year At €1.10
Dec 29Carl Zeiss Meditec (ETR:AFX) Has Announced That It Will Be Increasing Its Dividend To €1.10
Dec 14What Is Carl Zeiss Meditec AG's (ETR:AFX) Share Price Doing?
Nov 04Calculating The Intrinsic Value Of Carl Zeiss Meditec AG (ETR:AFX)
Oct 18Investors Will Want Carl Zeiss Meditec's (ETR:AFX) Growth In ROCE To Persist
Sep 12Carl Zeiss Meditec (ETR:AFX) Seems To Use Debt Rather Sparingly
Aug 25Returns On Capital At Carl Zeiss Meditec (ETR:AFX) Have Hit The Brakes
May 30Does Carl Zeiss Meditec (ETR:AFX) Have A Healthy Balance Sheet?
Feb 27Carl Zeiss Meditec's (ETR:AFX) Returns Have Hit A Wall
Feb 08Here's Why We Think Carl Zeiss Meditec (ETR:AFX) Is Well Worth Watching
Dec 12Carl Zeiss Meditec (ETR:AFX) Has Some Way To Go To Become A Multi-Bagger
Nov 06If You Like EPS Growth Then Check Out Carl Zeiss Meditec (ETR:AFX) Before It's Too Late
Sep 06Investors Met With Slowing Returns on Capital At Carl Zeiss Meditec (ETR:AFX)
Aug 08Here's Why We Think Carl Zeiss Meditec AG's (ETR:AFX) CEO Compensation Looks Fair for the time being
May 21Why Carl Zeiss Meditec's (ETR:AFX) Shaky Earnings Are Just The Beginning Of Its Problems
May 18Capital Allocation Trends At Carl Zeiss Meditec (ETR:AFX) Aren't Ideal
Apr 28Carl Zeiss Meditec AG's (ETR:AFX) Intrinsic Value Is Potentially 19% Below Its Share Price
Mar 09How Should Investors Feel About Carl Zeiss Meditec's (ETR:AFX) CEO Remuneration?
Feb 16
What Type Of Shareholders Own The Most Number of Carl Zeiss Meditec AG (ETR:AFX) Shares?
Jan 30Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 9/30/2026 | 2,485 | 280 | 258 | N/A | 13 |
| 9/30/2025 | 2,305 | 228 | 235 | N/A | 15 |
| 9/30/2024 | 2,076 | 163 | 176 | N/A | 15 |
| 6/30/2024 | 2,066 | 203 | N/A | N/A | N/A |
| 3/31/2024 | 2,062 | 261 | 122 | 263 | N/A |
| 12/31/2023 | 2,094 | 277 | N/A | N/A | N/A |
| 9/30/2023 | 2,089 | 290 | 137 | 251 | N/A |
| 6/30/2023 | 2,080 | 308 | N/A | N/A | N/A |
| 3/31/2023 | 2,022 | 278 | 63 | 162 | N/A |
| 12/31/2022 | 1,963 | 307 | N/A | N/A | N/A |
| 9/30/2022 | 1,903 | 294 | 106 | 188 | N/A |
| 6/30/2022 | 1,781 | 245 | N/A | N/A | N/A |
| 3/31/2022 | 1,735 | 264 | 207 | 285 | N/A |
| 12/31/2021 | 1,688 | 228 | N/A | N/A | N/A |
| 9/30/2021 | 1,647 | 236 | 297 | 363 | N/A |
| 6/30/2021 | 1,566 | 235 | N/A | N/A | N/A |
| 3/31/2021 | 1,388 | 159 | 240 | 290 | N/A |
| 12/31/2020 | 1,335 | 130 | N/A | N/A | N/A |
| 9/30/2020 | 1,335 | 122 | 134 | 179 | N/A |
| 6/30/2020 | 1,400 | 120 | N/A | N/A | N/A |
| 3/31/2020 | 1,507 | 166 | 132 | 171 | N/A |
| 12/31/2019 | 1,505 | 170 | N/A | N/A | N/A |
| 9/30/2019 | 1,459 | 160 | 173 | 220 | N/A |
| 6/30/2019 | 1,382 | 153 | N/A | N/A | N/A |
| 3/31/2019 | 1,334 | 129 | 195 | 242 | N/A |
| 12/31/2018 | 1,310 | 127 | N/A | N/A | N/A |
| 9/30/2018 | 1,281 | 126 | 152 | 187 | N/A |
| 6/30/2018 | 1,251 | 124 | N/A | N/A | N/A |
| 3/31/2018 | 1,216 | 129 | N/A | 56 | N/A |
| 12/31/2017 | 1,205 | 132 | N/A | N/A | N/A |
| 9/30/2017 | 1,190 | 134 | N/A | 38 | N/A |
| 6/30/2017 | 1,154 | 123 | N/A | N/A | N/A |
| 3/31/2017 | 1,135 | 112 | N/A | 85 | N/A |
| 12/31/2016 | 1,106 | 113 | N/A | N/A | N/A |
| 9/30/2016 | 1,088 | 98 | N/A | 112 | N/A |
| 6/30/2016 | 1,090 | 78 | N/A | 132 | N/A |
| 3/31/2016 | 1,083 | 80 | N/A | 96 | N/A |
| 12/31/2015 | 1,062 | 61 | N/A | 73 | N/A |
| 9/30/2015 | 1,040 | 62 | N/A | 57 | N/A |
| 6/30/2015 | 984 | 70 | N/A | 34 | N/A |
| 3/31/2015 | 946 | 66 | N/A | 44 | N/A |
| 12/31/2014 | 938 | 73 | N/A | 60 | N/A |
| 9/30/2014 | 909 | 75 | N/A | 63 | N/A |
| 6/30/2014 | 931 | 83 | N/A | 74 | N/A |
| 3/31/2014 | 924 | 89 | N/A | 69 | N/A |
| 12/31/2013 | 900 | 89 | N/A | 52 | N/A |
| 9/30/2013 | 906 | 92 | N/A | 65 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de AFX ( 18.4% par an) est supérieure au taux d'épargne ( 0.8% ).
Bénéfices vs marché: Les bénéfices de AFX ( 18.4% par an) devraient croître plus lentement que le marché German ( 20% par an).
Croissance élevée des bénéfices: Les bénéfices de AFX devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de AFX ( 8.4% par an) devrait croître plus rapidement que le marché German ( 5.2% par an).
Croissance élevée des revenus: Le chiffre d'affaires de AFX ( 8.4% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de AFX devrait être faible dans 3 ans ( 12.8 %).